Slide Left Slide Right
Accelmed invests in private and public HealthTech companies in the US, Europe and Israel
Accelmed merges mature HealthTech businesses with promising innovative companies, creating significant revenue growth and returns
Accelmed’s Buyout/platform and Growth strategies have proven to provide high value to investors and companies
Accelmed invests in private and public HealthTech companies in the US, Europe and Israel
Accelmed merges mature HealthTech businesses with promising innovative companies, creating significant revenue growth and returns
Accelmed’s Buyout/platform and Growth strategies have proven to provide high value to investors and companies
Accelmed invests in private and public HealthTech companies in the US, Europe and Israel
Accelmed merges mature HealthTech businesses with promising innovative companies, creating significant revenue growth and returns
Accelmed’s Buyout/platform and Growth strategies have proven to provide high value to investors and companies
 
 
 
 
 

 

Investing in mature HealthTech companies 

 

Accelmed is a US and Israel based investment firm, focused on value creation for medical device, diagnostics and digital health companies. Accelmed was founded in 2009 by Mori Arkin and Uri Geiger and invests in small / mid-cap private and public companies.

With its proven track record and large team of accomplished investment professionals, Accelmed’s vision is to create leading HealthTech players and outstanding returns by applying Buyout/Platform and Structured Growth strategies.

 

 

 

 

 

 
 
 
 
 

 

Buyout/Platform Strategy: Integrating commercial platforms with innovation and providing growth equity to foster significant value creation

 

Accelmed brings its acumen in medical devices and its presence in the US and Israel to the Platform Model, which has already been implemented with great success.

Under the Platform model, Accelmed integrates innovative and market-ready HealthTech technologies into existing mature commercial companies that are able to effectively distribute and commercialize the new products.

Accelmed makes significant equity investments of between $20M and $50M per platform. In certain cases, in combination with its co-investing partners, investment can be increased to up to $300M.

As part of this model we acquire a significant interest in established HealthTech companies in the US, Europe with revenues in excess of $30M and which have an experienced direct sales force.

 

Accelmed_Growth_Partners

 

Proceeds of our investments will be used for both organic and inorganic growth through the acquisition and integration of innovative market ready technologies identified and selected by Accelmed and the platform company management.

The acquired Israeli innovative companies will serve as ongoing sources for fast, innovative & cost-efficient R&D. 

 

 

Structured Growth Strategy: Commercially proven products (>$10M LTM revenue) In need for growth capital and expertise to accelerate. 

 

Under the Structured Growth Strategy, Accelmed invests in mature HealthTech companies with proven commercial traction (>$10M of revenue) in need of growth capital and Accelmed’s support to get to liquidity. 

 

We invest in de-risked mature growth stage companies:

  • By the time we invest companies have resolved: Development/Technical risk; Clinical Risk; Regulatory risk; Reimbursement Risk; Commercial Proof (>$10M LTM revenue)
  • Remaining is only Execution risk – addressed by AGP’s highly experienced team, which is involved hands-on in execution.
 

Platform Case Studies

Cogentix – Platform Model Case Study

The Platform Model is best illustrated through Accelmed Growth Partner’s investment in Cogentix (NASDAQ: CGNT). Cogentix offered three legacy product lines developed more than a decade ago and had sales of approximately $40M which were basically flat. It faced competition from larger players, such as Medtronic and had a significant debt ($29M).

Accelmed invested $25M in Cogentix in November 2016 and gained control over the company together with Mr. Lew Pell who converted his $29M of debt into equity. Dr. Uri Geiger became the Chairman of the company and a new CEO (Darrin Hammers) was nominated. In a little more than a year, Accelmed focused the company around its Urology product line, transforming the company into a dynamic, high growth company (18% annual growth) through both organic (investment in S&M) and in-organic (three add-on transactions) activities. The company’s share price has more than tripled in the 15 months since the announcement of the Accelmed investment. In March 2018 the company signed an agreement to be sold to Laborie for $240M in cash.

 

 

Endochoice – Platform Model Case Study

The Platform Model modus operandi can be also illustrated through the merger between Peer Medical, an Israeli company and developer of the Full Spectrum Endoscope, and EndoChoice, a gastroenterology (GI) player in Atlanta, GA, which had a solid commercial infrastructure but which lacked innovative products.

By merging Peer into EndoChoice and the addition of working capital, Accelmed was able to transform EndoChoice from a commodity player into a cutting edge technology company. The merger, carried out in 2013, led to Endochoice’s emergence as a leading, global, GI player with sales above $75M in 2015 (more than doubled since the merger), high double-digit growth and a presence in more than 25 countries. EndoChoice completed a successful IPO on June 2015 and was sold to Boston Scientific for $220M in October 2016.

 

new Endochoice case study

 

 

OIS – Platform Model Case Study

OIS is another example of the successful deployment of Accelmed’s Platform Model.

OIS, a California-based ophthalmic imaging systems player, acquired MediVision, the developer of an innovative retinal camera based on Israeli defense technology. The deal was financed and led by Accelmed, which held 44% of OIS’s shares post-merger in 2009. Within two years, OIS was sold, providing Accelmed with an outstanding return.

 

new OIS case study

 

 

 
 
 
 
 
 
 
 

Team

+
Mori Arkin
Co-Founder and Chairman of the Investment Committee
 
+
Dr. Uri Geiger
Co-Founder and Managing Partner
 
+
Dr. Irit Yaniv MD, MBA
General Partner
 
+
Ilan Ben Oren
Partner & CTO
 
+
Amir Blatt
Partner
 
+
Lior Shav
Partner
 
+
Dr. Rafael Torgovicky MD, MHA
Executive in Residence
 
+
Dr. Guy Ohad MD
Chief Medical Officer
 
+
Dr. Susan Alpert MD, PhD
Chief Regulatory Officer
 
+
Nir Gilad
Investment Manager
 
 

Executives Network

 

Accelmed enjoys close collaboration with a network of seasoned executives who have built, led and sold companies for billions of dollars. These executives assist Accelmed in identifying and analyzing potential opportunities and may serve in key leadership roles in future platform companies.

 
 
 
 
 
 
 

Buyout

+
Keystone Dental
Keystone Dental
 
+
Strata Skin Sciences
Strata Skin Sciences
 
+
Exalenz
Exalenz
 
 

Growth

+
EndoGastric Solutions
EndoGastric Solutions
 
 

Targeted Innovation

+
Corvia
Corvia
 
+
Valcare Medical
Valcare Medical
 
+
Digma
Digma
 
+
SoniVie
SoniVie
 
+
Cynerio
Cynerio
 
 

Incubator

+
Eximo Medical
Eximo Medical
 
+
Memic
Memic
 
+
NitiNotes
NitiNotes
 
+
ReVamp
ReVamp
 
 

Venture Capital

+
CartiHeal
CartiHeal
 
+
EndoSpan
EndoSpan
 
+
Nitiloop
Nitiloop
 
+
Pi-Cardia
Pi-Cardia
 
+
Tailormed
Tailormed
 
 

Sold Companies

+
Cogentix
Cogentix
 
+
Endochoice
Endochoice
 
+
Ophthalmic Imaging Systems
Ophthalmic Imaging Systems
 
+
Volcano
Volcano
 
+
Edge Medical Devices
Edge Medical Devices
 
+
MCS
MCS
 
+
NLT Spine
NLT Spine
 
 
Contact

US Office:
400 Madison Avenue, Suite 9B
New York, NY, 10017
Tel: +1-212-554-4601

Israel Office:
6 Hachoshlim St. 6th floor
Herzliya Pituach, 46120
Tel: +972-9-7885599

Email: info@accelmed.com